Search
Phenoxyethanol
go.drugbank.com/drugs/DB11304ApprovedInvestigationalIt is produced by reacting phenol (EU) and ethylene oxide (EU) at a high temperature and pressure. This substance occurs naturally in green tea (EU) [L2621]. … According to the European Union Cosmetics Regulation (EC) n.1223/2009, phenoxyethanol is authorized as a preservative in cosmetic formulations at a maximum concentration of 1.0% [L2625].
Sodium tartrate
go.drugbank.com/drugs/DB13707ApprovedWithdrawnIt acts as an emulsifier and pH control agent in food products [L2590]. … This compound is commonly used as an emulsifier in cheese/cheese spread products and is not to exceed 4% concentration, according to Health Canada regulations [L2594].
Pixantrone
go.drugbank.com/drugs/DB06193ApprovedWithdrawnAnother phase III trial, PIX-R, is now ongoing to clarify pixantrones place in therapy. It will compare pixantrone efficacy to that of gemcitabine. [2] … Based on this uncertainty, in 2009, the FDA ultimately rejected Cell Therapeutic's initial application for accelerated approval for pixantrone use in relapsed or refractory NHL.
Migalastat
go.drugbank.com/drugs/DB05018ApprovedInvestigationalThis enzyme is responsible for breaking down glycosphingolipid substrate that, when deficient in patients with Fabry disease, builds up in the blood vessels, the kidneys, the nerves, the heart, and other … [L47036,L47057,L4274,L4278] In the U.S., it is estimated that more than 3,000 people are living with Fabry disease, and an estimated more than 50 percent of these diagnosed patients are currently untreated
Flotufolastat F-18
go.drugbank.com/drugs/DB17851ApprovedInvestigational[A259846] In May 2023, the FDA approved the use of flotufolastat F-18 for PET of PSMA-positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive … therapy or suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.
Sipuleucel-T
go.drugbank.com/drugs/DB06688ApprovedInvestigationalThe treatment initially cost $93,000 at the time of FDA approval, but rose to over $100,000 in 2014. … Food and Drug Administration (FDA) on April 29, 2010, to treat asymptomatic or minimally symptomatic metastatic Hormone-Refractory Prostate Cancer (HRPC).
Relatlimab
go.drugbank.com/drugs/DB14851ApprovedInvestigational[L41300] Opdualag was subsequently approved in the European Union in July 2022[L49996] and in Canada in September 2023.[L50001] … [A246165,L41265] It was the first commercially developed anti-LAG-3 antibody, entering clinical trials in 2013,[A246155] and has garnered interest in the treatment of a variety of cancers, including leukemia
Aminoglutethimide
go.drugbank.com/drugs/DB00357ApprovedWithdrawn(From Martindale, The Extra Pharmacopoeia, 30th ed, p454) … Aminoglutethimide has been used in the treatment of advanced breast and prostate cancer. It was formerly used for its weak anticonvulsant properties.
Vadadustat
go.drugbank.com/drugs/DB12255ApprovedInvestigational[A244145,A244155] It was first approved in Japan in 2020,[L50371] and in April 2023, it was approved by the EMA for the treatment of symptomatic anemia associated with CKD in adults on chronic maintenance … [L39610,L46936,L46951] Vadadustat was approved by the FDA in March 2024.[L50371]
Synonyms: N-(5-(3-Chlorophenyl)-3-hydroxypyridine-2-carbonyl)glycine, Glycine, N-((5-(3-chlorophenyl)-3-hydroxy-2-pyridinyl)carbonyl)-Daprodustat
go.drugbank.com/drugs/DB11682ApprovedInvestigational[A254172] In June 2020, daprodustat was first approved in Japan for the treatment of renal anemia. … [L43857] On February 1, 2023, daprodustat was fully approved by the FDA as the first oral treatment for anemia caused by chronic kidney disease in patients on dialysis.
Synonyms: Glycine, N-((1,3-dicyclohexylhexahydro-2,4,6-trioxo-5-pyrimidinyl)carbonyl)-